Article

The Role of Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

A select group of hematologic oncologists participated in a virtual workshop to discuss the role of BTK inhibitors in the treatment of MCL and CLL Led by Kami Maddocks, MD; and Anthony Mato, MD. The expert panel shared insights on the available evidence regarding BTK inhibitors in MCL and CLL, novel treatment approaches, and optimal strategies for combining and sequencing therapies.

Related Videos
Tycel Phillips, MD, MPH
Pallawi Torka, MD
Carolyn Owen, MD, FRCPC
Alexey V. Danilov, MD, PhD
Kami J. Maddocks, MD
Matthew A. Lunning, DO, FACP
Anita Kumar, MD
Sarah Sammons, MD
Laura Spring, MD
Related Content
Best Practices in Treating Early-Stage NSCLC
July 11th 2024

Best Practices in Treating Early-Stage NSCLC

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer
April 11th 2024

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer
April 21st 2023

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

Clinical Decision Making in Advanced NSCLC without Actionable Mutations
April 21st 2023

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

BTK Inhibitors in MCL and CLL
March 10th 2023

BTK Inhibitors in MCL and CLL

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?
January 25th 2023

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?